These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 38226606

  • 1. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
    Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, Wang JR, Busaidy NL, Cabanillas ME.
    Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606
    [Abstract] [Full Text] [Related]

  • 2. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
    Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas ME.
    Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
    [Abstract] [Full Text] [Related]

  • 3. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
    Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME, Boran A, Ilankumaran P, Burgess P, Romero Salas T, Keam B.
    Ann Oncol; 2022 Apr; 33(4):406-415. PubMed ID: 35026411
    [Abstract] [Full Text] [Related]

  • 4. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.
    Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME.
    Thyroid; 2018 Jan; 28(1):79-87. PubMed ID: 29161986
    [Abstract] [Full Text] [Related]

  • 5. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
    Arıkan R, Telli TA, Demircan NC, Başoğlu T, Ercelep Ö, Atasoy BM, Özgüven S, Dane F, Yumuk PF.
    Curr Probl Cancer; 2021 Apr; 45(2):100668. PubMed ID: 33127167
    [Abstract] [Full Text] [Related]

  • 6. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
    Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B.
    J Clin Oncol; 2018 Jan 01; 36(1):7-13. PubMed ID: 29072975
    [Abstract] [Full Text] [Related]

  • 7. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA.
    Lancet Oncol; 2018 Feb 01; 19(2):181-193. PubMed ID: 29361468
    [Abstract] [Full Text] [Related]

  • 8. Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.
    da Silva TN, Rodrigues R, Saramago A, Pires C, Rito M, Horta M, Martins C, Leite V, Cavaco BM.
    Eur J Endocrinol; 2023 Jan 10; 188(1):. PubMed ID: 36651156
    [Abstract] [Full Text] [Related]

  • 9. Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer.
    Fazeli S, Paal E, Maxwell JH, Burman KD, Nylen ES, Khosla SG.
    J Investig Med High Impact Case Rep; 2019 Jan 10; 7():2324709619890942. PubMed ID: 31766881
    [Abstract] [Full Text] [Related]

  • 10. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.
    Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM, Long GV.
    Lancet Oncol; 2019 May 10; 20(5):701-710. PubMed ID: 30928620
    [Abstract] [Full Text] [Related]

  • 11. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAFV600E-mutated poorly differentiated thyroid cancer: A case report and review of the literature.
    Zeng Q, Deng Y, Zhang L, Wang W.
    Int J Clin Pharmacol Ther; 2022 May 10; 60(5):225-231. PubMed ID: 35072623
    [Abstract] [Full Text] [Related]

  • 12. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
    Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K.
    N Engl J Med; 2014 Nov 13; 371(20):1877-88. PubMed ID: 25265492
    [Abstract] [Full Text] [Related]

  • 13. Detection of BRAFV600E by digital PCR on fine-needle aspirate enables rapid initiation of dabrafenib and trametinib in unresectable anaplastic thyroid carcinoma.
    Buffet C, Allard L, Guillerm E, Ghander C, Mathy E, Lussey-Lepoutre C, Julien N, Touma E, Quilhot P, Godiris-Petit G, Lacorte JM, Leenhardt L, Denis JA.
    Eur J Endocrinol; 2022 Sep 01; 187(3):K33-K38. PubMed ID: 35900324
    [Abstract] [Full Text] [Related]

  • 14. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C.
    Lancet Oncol; 2015 Oct 01; 16(13):1389-98. PubMed ID: 26433819
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
    Dudnik E, Bar J, Peled N, Bshara E, Kuznetsov T, Cohen AY, Shochat T, Nechushtan H, Onn A, Agbarya A, Moskovitz M, Keren S, Popovits-Hadar N, Urban D, Mishaeli M, Rabinovich NM, Brenner R, Zer A, Rotem O, Roisman LC, Wollner M, Israel Lung Cancer Group.
    Clin Lung Cancer; 2019 Jul 01; 20(4):278-286.e1. PubMed ID: 31060855
    [Abstract] [Full Text] [Related]

  • 16. Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.
    Choi YS, Kwon H, You MH, Kim TY, Kim WB, Shong YK, Jeon MJ, Kim WG.
    Endocr Relat Cancer; 2022 May 09; 29(6):307-319. PubMed ID: 35343921
    [Abstract] [Full Text] [Related]

  • 17. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case Reports.
    White PS, Pudusseri A, Lee SL, Eton O.
    Thyroid; 2017 Sep 09; 27(9):1201-1205. PubMed ID: 28805135
    [Abstract] [Full Text] [Related]

  • 18. Laryngotracheal Resection After B-Raf Proto-oncogene Inhibition for Anaplastic Thyroid Carcinoma.
    Kent J, Erwin P, Haraf D, Liao CY, Durham J, Angelos P, Agrawal N, Baird BJ, Madariaga MLL.
    Ann Thorac Surg; 2023 May 09; 115(5):e117-e120. PubMed ID: 35504360
    [Abstract] [Full Text] [Related]

  • 19. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
    Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, de Braud F, Prager GW, Greil R, Stein A, Fasolo A, Schellens JHM, Wen PY, Viele K, Boran AD, Gasal E, Burgess P, Ilankumaran P, Wainberg ZA.
    Lancet Oncol; 2020 Sep 09; 21(9):1234-1243. PubMed ID: 32818466
    [Abstract] [Full Text] [Related]

  • 20. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
    Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ.
    Ann Oncol; 2017 Jul 01; 28(7):1631-1639. PubMed ID: 28475671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.